Novel 68Ga-Labeled Peptide PET Tracers Target Gastrin-Releasing Peptide Receptor for Cancer Imaging
Novel 68Ga-labeled GRPR-targeted PET tracers derived from peptide scaffolds showed improved tumor imaging characteristics for prostate and breast cancer diagnosis.
Quick Facts
What This Study Found
Novel 68Ga-labeled GRPR-targeted peptide PET tracers with improved tumor imaging for prostate/breast cancer through optimized peptide scaffold design.
Key Numbers
How They Did This
Peptide synthesis, 68Ga radiolabeling, GRPR binding affinity, biodistribution, and PET imaging in tumor models.
Why This Research Matters
Better cancer imaging leads to earlier detection and more accurate staging, improving treatment outcomes.
The Bigger Picture
Peptide-based PET tracers are becoming standard for cancer imaging, with GRPR targeting complementing PSMA imaging for comprehensive prostate cancer evaluation.
What This Study Doesn't Tell Us
Preclinical. Translation to clinical PET imaging needed.
Questions This Raises
- ?How do these tracers compare to existing GRPR imaging agents?
- ?Could they be paired with therapeutic radionuclides for theranostics?
- ?Would combined GRPR+PSMA imaging improve prostate cancer management?
Trust & Context
- Key Stat:
- Peptide sees cancer Novel peptide tracers labeled with gallium-68 enable PET imaging to detect cancers expressing the gastrin-releasing peptide receptor
- Evidence Grade:
- Preclinical tracer development with imaging validation.
- Study Age:
- Published in 2025.
- Original Title:
- Synthesis and Evaluation of Novel 68Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe6,Pro14]Bombesin(6-14) and [d-Phe6,des-Met14]Bombesin(6-14) Sequences.
- Published In:
- Molecular pharmaceutics, 23(3), 1985-1995 (2026)
- Authors:
- Jozi, Shireen, Pathania, Sheetal, Wang, Lei(12), Chen, Chao-Cheng, Lau, Wing Sum, Ng, Pauline, Merkens, Helen, Bénard, François, Lin, Kuo-Shyan
- Database ID:
- RPEP-15394
Evidence Hierarchy
Frequently Asked Questions
How do peptides help find cancer?
Peptides that bind to specific cancer cell receptors (GRPR) are labeled with radioactive gallium-68. When injected, they concentrate at tumors and light up on PET scans for precise cancer detection.
Which cancers can this detect?
GRPR is overexpressed in prostate, breast, and other cancers. These peptide tracers provide a non-invasive way to detect and stage these tumors.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15394APA
Jozi, Shireen; Pathania, Sheetal; Wang, Lei; Chen, Chao-Cheng; Lau, Wing Sum; Ng, Pauline; Merkens, Helen; Bénard, François; Lin, Kuo-Shyan. (2026). Synthesis and Evaluation of Novel 68Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe6,Pro14]Bombesin(6-14) and [d-Phe6,des-Met14]Bombesin(6-14) Sequences.. Molecular pharmaceutics, 23(3), 1985-1995. https://doi.org/10.1021/acs.molpharmaceut.5c01683
MLA
Jozi, Shireen, et al. "Synthesis and Evaluation of Novel 68Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe6,Pro14]Bombesin(6-14) and [d-Phe6,des-Met14]Bombesin(6-14) Sequences.." Molecular pharmaceutics, 2026. https://doi.org/10.1021/acs.molpharmaceut.5c01683
RethinkPeptides
RethinkPeptides Research Database. "Synthesis and Evaluation of Novel 68Ga-Labeled GRPR-Targeted..." RPEP-15394. Retrieved from https://rethinkpeptides.com/research/jozi-2026-synthesis-and-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.